

Juhaeri Juhaeri

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1550168/juhaeri-juhaeri-publications-by-year.pdf>

Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

38 papers	566 citations	14 h-index	22 g-index
41 ext. papers	800 ext. citations	4.7 avg, IF	3.96 L-index

#	Paper	IF	Citations
38	Evaluating the Risk of Digitalis Intoxication Associated With Concomitant Use of Dronedaron and Digoxin Using Real-World Data. <i>Clinical Therapeutics</i> , 2021 , 43, 852-858.e2	3.5	
37	Risk of interstitial lung disease in patients treated for atrial fibrillation with dronedarone versus other antiarrhythmics. <i>Pharmacoepidemiology and Drug Safety</i> , 2021 , 30, 1353-1359	2.6	2
36	Incidence of diabetic ketoacidosis and its trends in patients with type 1 diabetes mellitus identified using a U.S. claims database, 2007-2019. <i>Journal of Diabetes and Its Complications</i> , 2021 , 35, 107932	3.2	1
35	Performance assessment of different machine learning approaches in predicting diabetic ketoacidosis in adults with type 1 diabetes using electronic health records data. <i>Pharmacoepidemiology and Drug Safety</i> , 2021 , 30, 610-618	2.6	2
34	Appraising patient preference methods for decision-making in the medical product lifecycle: an empirical comparison. <i>BMC Medical Informatics and Decision Making</i> , 2020 , 20, 114	3.6	2
33	Age- and sex-specific incidence of non-traumatic lower limb amputation in patients with type 2 diabetes mellitus in a U.S. claims database. <i>Diabetes Research and Clinical Practice</i> , 2020 , 169, 108452	7.4	4
32	Structured benefit-risk evaluation for medicinal products: review of quantitative benefit-risk assessment findings in the literature. <i>Therapeutic Advances in Drug Safety</i> , 2020 , 11, 2042098620976951	3.5	3
31	Benefit-risk evaluation: the past, present and future. <i>Therapeutic Advances in Drug Safety</i> , 2019 , 10, 2042098619871180	3.5	3
30	Patient Preferences in the Medical Product Life Cycle: What do Stakeholders Think? Semi-Structured Qualitative Interviews in Europe and the USA. <i>Patient</i> , 2019 , 12, 513-526	3.7	13
29	Methods for exploring and eliciting patient preferences in the medical product lifecycle: a literature review. <i>Drug Discovery Today</i> , 2019 , 24, 1324-1331	8.8	37
28	Proximal HbA1C Level and First Hypoglycemia Hospitalization in Adults With Incident Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019 , 104, 1989-1998	5.6	1
27	Comparison of text processing methods in social media-based signal detection. <i>Pharmacoepidemiology and Drug Safety</i> , 2019 , 28, 1309-1317	2.6	4
26	Factors and Situations Affecting the Value of Patient Preference Studies: Semi-Structured Interviews in Europe and the US. <i>Frontiers in Pharmacology</i> , 2019 , 10, 1009	5.6	8
25	Opportunities and challenges for the inclusion of patient preferences in the medical product life cycle: a systematic review. <i>BMC Medical Informatics and Decision Making</i> , 2019 , 19, 189	3.6	11
24	Design, Conduct, and Use of Patient Preference Studies in the Medical Product Life Cycle: A Multi-Method Study. <i>Frontiers in Pharmacology</i> , 2019 , 10, 1395	5.6	22
23	Factors and situations influencing the value of patient preference studies along the medical product lifecycle: a literature review. <i>Drug Discovery Today</i> , 2019 , 24, 57-68	8.8	38
22	Assessing the Risk for Peripheral Neuropathy in Patients Treated With Dronedaron Compared With That in Other Antiarrhythmics. <i>Clinical Therapeutics</i> , 2018 , 40, 450-455.e1	3.5	7

21	Trends in Hospital Admission for Diabetic Ketoacidosis in Adults With Type 1 and Type 2 Diabetes in England, 1998-2013: A Retrospective Cohort Study. <i>Diabetes Care</i> , 2018 , 41, 1870-1877	14.6	61
20	HbA variability and hypoglycemia hospitalization in adults with type 1 and type 2 diabetes: A nested case-control study. <i>Journal of Diabetes and Its Complications</i> , 2018 , 32, 203-209	3.2	17
19	Web-Based Signal Detection Using Medical Forums Data in France: Comparative Analysis. <i>Journal of Medical Internet Research</i> , 2018 , 20, e10466	7.6	11
18	Validation of New Signal Detection Methods for Web Query Log Data Compared to Signal Detection Algorithms Used With FAERS. <i>Drug Safety</i> , 2017 , 40, 399-408	5.1	8
17	Dietary intake and risk of non-severe hypoglycemia in adolescents with type 1 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2017 , 31, 1340-1347	3.2	10
16	Incidence and Trends in Hypoglycemia Hospitalization in Adults With Type 1 and Type 2 Diabetes in England, 1998-2013: A Retrospective Cohort Study. <i>Diabetes Care</i> , 2017 , 40, 1651-1660	14.6	35
15	Recommendations for benefit-risk assessment methodologies and visual representations. <i>Pharmacoepidemiology and Drug Safety</i> , 2016 , 25, 251-62	2.6	34
14	Intranasal triamcinolone use during pregnancy and the risk of adverse pregnancy outcomes. <i>Journal of Allergy and Clinical Immunology</i> , 2016 , 138, 97-104.e7	11.5	22
13	The US Food and Drug Administration's Risk Evaluation and Mitigation Strategy (REMS) Program - Current Status and Future Direction. <i>Clinical Therapeutics</i> , 2016 , 38, 2526-2532	3.5	10
12	The risk of acute liver injury associated with the use of antibiotics--evaluating robustness of results in the pharmacoepidemiological research on outcomes of therapeutics by a European consortium (PROTECT) project. <i>Pharmacoepidemiology and Drug Safety</i> , 2016 , 25 Suppl 1, 47-55	2.6	7
11	Risk of Wernicke's encephalopathy and cardiac disorders in patients with myeloproliferative neoplasm. <i>Cancer Epidemiology</i> , 2015 , 39, 242-9	2.8	9
10	Benefit-Risk Assessment, Communication, and Evaluation (BRACE) throughout the life cycle of therapeutic products: overall perspective and role of the pharmacoepidemiologist. <i>Pharmacoepidemiology and Drug Safety</i> , 2015 , 24, 1233-40	2.6	19
9	Assessment of dronedarone utilization using US claims databases. <i>Clinical Therapeutics</i> , 2014 , 36, 264-72.e2	3.5	7
8	Benefit-risk assessment in a post-market setting: a case study integrating real-life experience into benefit-risk methodology. <i>Pharmacoepidemiology and Drug Safety</i> , 2014 , 23, 974-83	2.6	17
7	Risk of Cardiovascular Events, Stroke, Congestive Heart Failure, Interstitial Lung Disease, and Acute Liver Injury: Dronedarone versus Amiodarone and Other Antiarrhythmics. <i>Journal of Atrial Fibrillation</i> , 2013 , 6, 890	0.8	8
6	Evaluation of dronedarone use in the US patient population between 2009 and 2010: a descriptive study using a claims database. <i>Clinical Therapeutics</i> , 2011 , 33, 1483-1490.e3	3.5	6
5	Predicting the risk of end-stage renal disease in the population-based setting: a retrospective case-control study. <i>BMC Nephrology</i> , 2011 , 12, 17	2.7	18
4	Incidence rates of heart failure, stroke, and acute myocardial infarction among Type 2 diabetic patients using insulin glargine and other insulin. <i>Pharmacoepidemiology and Drug Safety</i> , 2009 , 18, 497-503	2.6	26

3	The incidence rate of seizures in relation to BMI in UK adults. <i>Obesity</i> , 2008 , 16, 2126-32	8	7
2	Benefit-risk analysis: examples using quantitative methods. <i>Pharmacoepidemiology and Drug Safety</i> , 2003 , 12, 693-7	2.6	22
1	Benefit-risk analysis: a proposal using quantitative methods. <i>Pharmacoepidemiology and Drug Safety</i> , 2003 , 12, 611-6	2.6	43